Literature DB >> 27684277

Psychosocial interventions for psychostimulant misuse.

Silvia Minozzi1, Rosella Saulle, Franco De Crescenzo, Laura Amato.   

Abstract

BACKGROUND: Psychostimulant misuse is a continuously growing medical and social burden. There is no evidence proving the efficacy of pharmacotherapy. Psychosocial interventions could be a valid approach to help patients in reducing or ceasing drug consumption.
OBJECTIVES: To assess the effects of psychosocial interventions for psychostimulant misuse in adults. SEARCH
METHODS: We searched the Cochrane Drugs and Alcohol Group Specialised Register (via CRSLive); Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; CINAHL; Web of Science and PsycINFO, from inception to November 2015. We also searched for ongoing and unpublished studies via ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/).All searches included non-English language literature. We handsearched references of topic-related systematic reviews and the included studies. SELECTION CRITERIA: We included randomised controlled trials comparing any psychosocial intervention with no intervention, treatment as usual (TAU) or a different intervention in adults with psychostimulant misuse or dependence. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. MAIN
RESULTS: We included a total of 52 trials (6923 participants).The psychosocial interventions considered in the studies were: cognitive behavioural therapy (19 studies), contingency management (25 studies), motivational interviewing (5 studies), interpersonal therapy (3 studies), psychodynamic therapy (1 study), 12-step facilitation (4 studies).We judged most of the studies to be at unclear risk of selection bias; blinding of personnel and participants was not possible for the type of intervention, so all the studies were at high risk of performance bias with regard to subjective outcomes; the majority of studies did not specify whether the outcome assessors were blind. We did not consider it likely that the objective outcomes were influenced by lack of blinding.The comparisons made were: any psychosocial intervention versus no intervention (32 studies), any psychosocial intervention versus TAU (6 studies), and one psychosocial intervention versus an alternative psychosocial intervention (13 studies). Five of included studies did not provide any useful data for inclusion in statistical synthesis.We found that, when compared to no intervention, any psychosocial treatment: reduced the dropout rate (risk ratio (RR): 0.83, 95% confidence interval (CI) 0.76 to -0.91, 24 studies, 3393 participants, moderate quality evidence); increased continuous abstinence at the end of treatment (RR: 2.14, 95% CI 1.27 to -3.59, 8 studies, 1241 participants, low quality evidence); did not significantly increase continuous abstinence at the longest follow-up (RR: 2.12, 95% CI 0.77 to -5.86, 4 studies, 324 participants, low quality evidence); significantly increased the longest period of abstinence: (standardised mean difference (SMD): 0.48, 95% CI 0.34 to 0.63, 10 studies, 1354 participants, high quality evidence). However, it should be noted that the in the vast majority of the studies in this comparison the specific psychosocial treatment assessed in the experimental arm was given in add on to treatment as usual or to another specific psychosocial or pharmacological treatment which was received by both groups. So, many of the control groups in this comparison were not really untreated. Receiving some amount of treatment is not the same as not receiving any intervention, so we could argue that the overall effect of the experimental psychosocial treatment could be smaller if given in add on to TAU or to another intervention than if given to participants not receiving any intervention; this could translate to a smaller magnitude of the effect of the psychosocial intervention when it is given in add on.When compared to TAU, any psychosocial treatment reduced dropout rate (RR: 0.72, 95% CI 0.59 to 0.89, 6 studies, 516 participants, moderate quality evidence), did not increase continuous abstinence at the end of treatment (RR: 1.27, 95% CI 0.94 to 1.72, 2 studies, 224 participants, low quality evidence), did not increase longest period of abstinence (MD -3.15 days, 95% CI -10.35 to 4.05, 1 study, 110 participants, low quality evidence). No studies in this comparison assessed the outcome of continuous abstinence at longest follow-up.There were few studies comparing two or more psychosocial interventions, with small sample sizes and considerable heterogeneity in terms of the types of interventions assessed. None reported significant results.None of the studies reported harms related to psychosocial interventions. AUTHORS'
CONCLUSIONS: The addition of any psychosocial treatment to treatment as usual (usually characterised by group counselling or case management) probably reduces the dropout rate and increases the longest period of abstinence. It may increase the number of people achieving continuous abstinence at the end of treatment, although this might not be maintained at longest follow-up. The most studied and the most promising psychosocial approach to be added to treatment as usual is probably contingency management. However, the other approaches were only analysed in a few small studies, so we cannot rule out the possibility that the results were not significant because of imprecision. When compared to TAU, any psychosocial treatment may improve adherence, but it may not improve abstinence at the end of treatment or the longest period of abstinence.The majority of the studies took place in the United States, and this could limit the generalisability of the findings, because the effects of psychosocial treatments could be strongly influenced by the social context and ethnicity. The results of our review do not answer the most relevant clinical question, demonstrating which is the most effective type of psychosocial approach.Further studies should directly compare contingency management with the other psychosocial approaches.

Entities:  

Year:  2016        PMID: 27684277      PMCID: PMC6457581          DOI: 10.1002/14651858.CD011866.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  200 in total

1.  Follow-up results of supportive versus behavioral therapy for illicit drug use.

Authors:  N H Azrin; R Acierno; E S Kogan; B Donohue; V A Besalel; P T McMahon
Journal:  Behav Res Ther       Date:  1996-01

2.  Twelve-step and mutual-help programs for addictive disorders.

Authors:  J N Chappel; R L DuPont
Journal:  Psychiatr Clin North Am       Date:  1999-06

3.  The effect of 12-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients.

Authors:  Roger D Weiss; Margaret L Griffin; Robert J Gallop; Lisa M Najavits; Arlene Frank; Paul Crits-Christoph; Michael E Thase; Jack Blaine; David R Gastfriend; Dennis Daley; Lester Luborsky
Journal:  Drug Alcohol Depend       Date:  2005-02-14       Impact factor: 4.492

4.  The National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Rationale and methods.

Authors:  P Crits-Christoph; L Siqueland; J Blaine; A Frank; L Luborsky; L S Onken; L Muenz; M E Thase; R D Weiss; D R Gastfriend; G Woody; J P Barber; S F Butler; D Daley; S Bishop; L M Najavits; J Lis; D Mercer; M L Griffin; K Moras; A T Beck
Journal:  Arch Gen Psychiatry       Date:  1997-08

5.  Stimulant abuser groups to engage in 12-step: a multisite trial in the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Dennis M Donovan; Dennis C Daley; Gregory S Brigham; Candace C Hodgkins; Harold I Perl; Sharon B Garrett; Suzanne R Doyle; Anthony S Floyd; Patricia C Knox; Christopher Botero; Thomas M Kelly; Therese K Killeen; Carole Hayes; Nicole Kau'i Baumhofer; Nicole Kau'ibaumhofer; Cindy Seamans; Lucy Zammarelli
Journal:  J Subst Abuse Treat       Date:  2012-05-31

6.  Adding integrative meditation with ear acupressure to outpatient treatment of cocaine addiction: a randomized controlled pilot study.

Authors:  Kevin W Chen; Christine C Berger; Devang Gandhi; Eric Weintraub; C W Lejuez
Journal:  J Altern Complement Med       Date:  2012-10-12       Impact factor: 2.579

Review 7.  Psychosocial interventions for psychostimulant misuse.

Authors:  Silvia Minozzi; Rosella Saulle; Franco De Crescenzo; Laura Amato
Journal:  Cochrane Database Syst Rev       Date:  2016-09-29

8.  Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: six-month outcomes.

Authors:  Roberto Secades-Villa; Olaya García-Rodríguez; Stephen T Higgins; José R Fernández-Hermida; José L Carballo
Journal:  J Subst Abuse Treat       Date:  2007-05-23

9.  Employment-based abstinence reinforcement as a maintenance intervention for the treatment of cocaine dependence: a randomized controlled trial.

Authors:  Anthony DeFulio; Wendy D Donlin; Conrad J Wong; Kenneth Silverman
Journal:  Addiction       Date:  2009-09       Impact factor: 6.526

10.  Randomized trial of contingent prizes versus vouchers in cocaine-using methadone patients.

Authors:  Nancy M Petry; Sheila M Alessi; Tressa Hanson; Sean Sierra
Journal:  J Consult Clin Psychol       Date:  2007-12
View more
  30 in total

1.  Treatment of amphetamine abuse/use disorder: a systematic review of a recent health concern.

Authors:  Mansour Khoramizadeh; Mohammad Effatpanah; Alireza Mostaghimi; Mehdi Rezaei; Alireza Mahjoub; Sara Shishehgar
Journal:  Daru       Date:  2019-06-21       Impact factor: 3.117

2.  Crystal methamphetamine use subgroups and associated addiction care access and overdose risk in a Canadian urban setting.

Authors:  Olivia Brooks; Paxton Bach; Huiru Dong; M-J Milloy; Nadia Fairbairn; Thomas Kerr; Kanna Hayashi
Journal:  Drug Alcohol Depend       Date:  2022-01-11       Impact factor: 4.492

Review 3.  Psychosocial interventions for psychostimulant misuse.

Authors:  Silvia Minozzi; Rosella Saulle; Franco De Crescenzo; Laura Amato
Journal:  Cochrane Database Syst Rev       Date:  2016-09-29

4.  Monitoring cocaine use and abstinence among cocaine users for contingency management interventions.

Authors:  August F Holtyn; Todd W Knealing; Brantley P Jarvis; Shrinidhi Subramaniam; Kenneth Silverman
Journal:  Psychol Rec       Date:  2017-04-25

5.  The Prevalence of Methamphetamine Dependence among Iranian Women in Methadone Maintenance Therapy in Tehran, Iran.

Authors:  Omid Massah; Afsaneh Moradi
Journal:  Iran J Psychiatry       Date:  2018-01

6.  Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.

Authors:  Brian Chan; Karli Kondo; Michele Freeman; Chelsea Ayers; Jessica Montgomery; Devan Kansagara
Journal:  J Gen Intern Med       Date:  2019-06-10       Impact factor: 5.128

Review 7.  The phenomics and genetics of addictive and affective comorbidity in opioid use disorder.

Authors:  Philip J Freda; Jason H Moore; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2021-02-22       Impact factor: 4.492

Review 8.  Responding to global stimulant use: challenges and opportunities.

Authors:  Michael Farrell; Natasha K Martin; Emily Stockings; Annick Bórquez; Javier A Cepeda; Louisa Degenhardt; Robert Ali; Lucy Thi Tran; Jürgen Rehm; Marta Torrens; Steve Shoptaw; Rebecca McKetin
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

Review 9.  All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis.

Authors:  Amy Peacock; Lucy Thi Tran; Sarah Larney; Emily Stockings; Thomas Santo; Hayley Jones; Damian Santomauro; Louisa Degenhardt
Journal:  Addiction       Date:  2020-09-21       Impact factor: 6.526

10.  Psychosocial Interventions for Amphetamine Type Stimulant Use Disorder: An Overview of Systematic Reviews.

Authors:  Mai Thi Ngoc Tran; Quang Hung Luong; Giang Le Minh; Michael P Dunne; Philip Baker
Journal:  Front Psychiatry       Date:  2021-06-17       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.